Logo
K

Kynos Therapeutics Ltd.

8 employees

Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Therapeutics
Immunometabolism
Inflammation
Medical
Health Care
Oncology
Drug development

Date founded

2020

Funding rounds raised

Total raised

$8.5M

from 4 investors over 4 rounds

K

Kynos Therapeutics Ltd. raised $8.5M on April 7, 2022

Investors: Epidarex Capital, Scottish Enterprise and IP Group plc

K

Kynos Therapeutics Ltd. raised $3.3M on April 7, 2022

Investors: Innovate UK

FAQ